Clinical Trials | September 05, 2025
AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
The medicine was well tolerated, with no unexpected safety issue
The medicine was well tolerated, with no unexpected safety issue
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Subscribe To Our Newsletter & Stay Updated
